Working as a bilingual lawyer, Liang Xu has advised on many cross-border M&A transactions, both for Western corporations doing business in China, as well as Chinese enterprises (including SOEs and private companies) looking to expand and invest in global markets. His practice encompasses a variety of industries, including technology, automobile, manufacturing, energy, real estate, entertainment, educational and others. He has vast experience working with Chinese companies both as clients and as opponents, and is skilled in bringing the two sides of a dispute/transaction to a negotiated deal. Prior to joining Hogan Lovells in 2004, Liang was an in-house counsel with China Eastern Airlines Corporation Limited based in Shanghai.
Liang initially focused his practice on joint ventures, private equity and direct foreign investment matters for multinational clients. In recent years, with more and more Chinese companies going global, he has developed skills in advising and guiding Chinese companies through the Western style deal process, which is complicated for players from China who typically have insufficient global experience. Liang Xu is qualified in China and the New York State in the U.S., and is nominated as one of the Chambers Global leaders in the field of Corporate/M&A in China.
Representing China Cinda on the acquisition of a real estate development project in Beijing for US$1.6bn.
Representing a China based private equity fund in its proposed US$320m investment in a Hollywood movie studio.
Representing a major Chinese e-commerce company in relation to its joint venture in Southeast Asia.
Representing KPP in relation to its US$650m acquisition of selected assets from Eastman Kodak Company, including assets and entities in China.
TE Connectivity in its acquisition of two private Chinese companies in Xiamen.
Texas Instruments in acquiring a major Chinese semiconductor manufacturing facility in Chengdu.
ALSTOM in the public takeover of Wuhan Boiler, a company listed on Shenzhen Stock Exchange.
Actavis in its acquisition and disposal of several pharm manufacturing facilities in China.
Advising a global pharmaceutical company in its acquisition and disposal of several pharm manufacturing facilities in China.
Advising a Chinese manufacturer in its investment in a private equity backed high tech company based in the UK and U.S.
Latest thinking and events
Beijing: 29 November 2016, 8:15 a.m. to 1 p.m.
Shanghai: 2 December 2016, 8:15 a.m. to 1 p.m.
Sponsorships and Speaking Engagements
17 September 2016